← Eichor
Condition: Metastatic Pancreatic Neuroendocrine Tumor Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Metastatic Pancreatic Neuroendocrine Tumor

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of MGC026 in Participants With Advanced Solid Tumors
Phase 1 · 12 location(s) · MacroGenics · NCT06242470Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Phase 1 · 1 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT03454035Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
Phase 2/Phase 3 · 117 location(s) · Exelixis · NCT06943755SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Phase N/A · 68 location(s) · Massive Bio, Inc. · NCT03452774Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors
Phase 1 · 1 location(s) · University of Chicago · NCT06663072A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
NA · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT05837767Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI
Phase 2 · 22 location(s) · UNICANCER · NCT06333314High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies
NA · 1 location(s) · M.D. Anderson Cancer Center · NCT05053555Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Phase 1/Phase 2 · 21 location(s) · Revolution Medicines, Inc. · NCT05379985MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
Phase 1 · 2 location(s) · Memgen, Inc. · NCT05076760Electrochemotherapy (ECT) in Patients With Primary Visceral Tumors and/or Secondary Visceral Localizations, of Any Histo
NA · 1 location(s) · Istituto Oncologico Veneto IRCCS · NCT06753136Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT07410494A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic So
Phase 2 · 119 location(s) · Daiichi Sankyo · NCT06330064SL-28 for Advanced Solid Tumours
Phase 1/Phase 2 · 1 location(s) · Second Life Therapeutics · NCT07341737Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors
Phase 1 · 10 location(s) · National Cancer Institute (NCI) · NCT05687123A Beta-only IL-2 ImmunoTherapY Study
Phase 1/Phase 2 · 27 location(s) · Medicenna Therapeutics, Inc. · NCT05086692A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Phase 2 · 85 location(s) · Daiichi Sankyo · NCT06172478Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objective
NA · 1 location(s) · M.D. Anderson Cancer Center · NCT01365169Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
Phase 2 · 448 location(s) · SWOG Cancer Research Network · NCT05040360Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown
Phase 2 · 6 location(s) · Centre Hospitalier Universitaire Dijon · NCT04325425Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
NA · 1 location(s) · Cedars-Sinai Medical Center · NCT04907643Integrated Cancer Repository for Cancer Research
Phase N/A · 42 location(s) · University of Nebraska · NCT02012699FTT PET/CT in Pancreatic Neuroendocrine Tumors
Phase 1 · 1 location(s) · Abramson Cancer Center at Penn Medicine · NCT07114939Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT01174121EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT07410676Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuro
Phase 2 · 1 location(s) · Roswell Park Cancer Institute · NCT06202066Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroend
Phase 4 · 1 location(s) · Vanderbilt-Ingram Cancer Center · NCT06016855Safety and Efficacy of KLS-1 Monotherapy in Malignant Neoplasms
Phase 1/Phase 2 · 1 location(s) · Vector Vitale LLC · NCT06506643Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid
Phase 1 · 3 location(s) · Anusha Kalbasi · NCT04119024Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70
Phase 1/Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT02830724
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.